Engflag

Karteol

Quick links to important sections

Karteol

Karteol_EN

Method of action: Ophthalmologicals

Treatment option: Intraocular Hypertension, Hypertension, Glaucoma

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karteol

Property Description
Active ingredient Carteolol Hydrochloride
Form Ophthalmic Solution (Eye drops) and Tablets
Pharmacological class Adrenergic beta-Antagonist (Beta-Blocker)
Common use Pressure regulation within the eye
Origin Synthetic (Quinolone derivative)

What Type of Medicine is Carteol (Carteolol Hydrochloride)?

Karteol is a medicine whose active substance is the generic compound Carteolol Hydrochloride, fundamentally classified as an Adrenergic beta-Antagonist, commonly known as a Beta-Blocker. The compound is synthetic, structurally defined as a quinolone derivative, and its classification establishes its primary function: the modulation of nerve signals by blocking the effects of stimulating compounds like adrenaline.

Carteolol Hydrochloride is characterized by its Intrinsic Sympathomimetic Activity (ISA), a distinctive feature among beta-blockers. This means that while the substance primarily acts to block receptors, it simultaneously maintains a minimal, inherent level of partial stimulation, providing a differentiated pharmacological profile.

What Forms of Carteolol Exist and How Are They Used?

The active ingredient is manufactured as a single-ingredient product, appearing most commonly in the form of an Ophthalmic Solution (eye drops) for ocular (topical) administration, where the Carteolol Hydrochloride is dissolved in an aqueous solution. The same substance may also be formulated as Tablets for oral (systemic) use.

The Ophthalmic Solution is specifically designed for localized action at the eye, distinguishing its application from the systemic absorption achieved with the tablet form. This topical route ensures that the drug's effect is concentrated locally, a critical feature for its typical use scenario involving pressure balance in the eye.

What Is the General Purpose of This Beta-Blocker?

The general therapeutic purpose of Carteolol in its ophthalmic form is the control of fluid pressure, leading to its classification as an Antiglaucoma Agent. The medication works by modulating the natural activity responsible for the generation of the clear, internal fluid inside the eyeball.

This primary physiological action is clinically recognized for its ability to slow down the rate of fluid production, which is the fundamental mechanism responsible for lowering the internal pressure within the eye. A typical use scenario involves a patient requiring assistance to maintain stable pressure within the ocular structure.

Regulatory References

  1. DailyMed Labeling (NIH)
  2. MedlinePlus (NIH)

What side effects are possible with Karteol?

Possible Side Effects and Safety Information

The safety profile of Carteolol Hydrochloride Ophthalmic Solution, as documented in regulatory labeling, reflects both localized ocular effects and the potential for systemic effects consistent with its class as a beta-adrenergic blocking agent.

Commonly Documented Adverse Reactions

The most frequently reported adverse effects are localized to the eye. Regulatory documents classify these as Very Common, affecting approximately one in four patients in clinical trials, and include transient eye irritation, burning, excessive tearing, and conjunctival hyperemia (redness).

Systemic Effects and Organ Classes

Systemic absorption of the topical solution means that adverse reactions can involve multiple System-Organ Classes. Less Common systemic effects reported occasionally include bradycardia (slow heart rate), shortness of breath, dizziness, and chest pain. Other systems with documented effects include the Nervous System (e.g., headache, asthenia) and Gastrointestinal Disorders.

Serious Adverse Reactions and Contraindications

Official prescribing information documents the potential for serious reactions consistent with systemic beta-blockade. These include rare reports of severe bronchospasm (including fatalities in patients with asthma) and serious cardiac events such as cardiac arrest and the aggravation of overt cardiac failure. Due to these risks, the medicine is contraindicated for patients with bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, or overt cardiac failure. Safety notes also indicate that beta-blockers may mask the signs of acute hypoglycemia in diabetic patients and may lead to additive systemic effects (hypotension, marked bradycardia) if co-administered with other cardiovascular medicines.

Overdose and Emergency Response

Overdose Scope

Category Official Regulatory Statement
Documented overdose presentations Clinical signs expected from systemic beta-adrenergic blocking activity, including bradycardia (slow heart rate), hypotension (low blood pressure), and bronchospasm (airway narrowing).
Physiological systems affected Cardiovascular system (leading to bradycardia, hypotension, and Congestive Heart Failure), and Respiratory system.
Dose-related or exposure-related factors Overdose risk is associated with accidental ocular overdosage or systemic over-absorption of the active substance.
Population-specific overdose notes No specific population-based differences are explicitly detailed in the official overdosage section.
Emergency-response statements For accidental ocular overdosage, flush eye(s) with water or normal saline. Following suspected ingestion, the patient must be closely observed and vital signs carefully monitored.

Overdose Classifications (High-Level)

Category Official Regulatory Statement
Severity classification Manifestations range from physiological signs (bradycardia) to potentially life-threatening outcomes (Congestive Heart Failure).
Regulatory basis Information derived from FDA Prescribing Information and supporting regulatory documents.
Overdose-context constraints No specific information on emergency treatment of overdosage in humans is available; management must be based on the general pharmacological profile of beta-adrenergic blocking agents.

Resulting Overdose Structure

Official overdose statements:

  • Life-threatening conditions such as Congestive Heart Failure are documented manifestations of systemic over-absorption and require immediate attention.
  • Management is strictly symptomatic and supportive, utilizing specific therapeutic agents (e.g., atropine for bradycardia, vasopressors for hypotension, beta2-stimulating agents for bronchospasm) to correct specific clinical signs.
  • Accidental ocular overdose requires flushing the eye(s) with water or normal saline, which is the mandated immediate local action.
  • The patient must be closely observed, and vital signs carefully monitored following suspected systemic overdosage.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by listing the expected manifestations of systemic beta-blockade, including bradycardia, hypotension, and Congestive Heart Failure, establishing the clinical basis for intervention. These official sources mandate immediate corrective actions for both local ocular exposure and systemic over-absorption, specifying that supportive procedures are necessary. The regulatory guidance requires that due to the potential for severe symptoms, urgent medical help must be sought when systemic overdosage is suspected.

Therapeutic Uses of Karteol

What Karteol Treats: Main Uses and Benefits

Carteolol ophthalmic solution is a medication used to manage conditions associated with fluid pressure inside the eye, and may assist with managing symptoms related to ocular functional stress. Its therapeutic function is classified as an Antiglaucoma Agent, applied across domains where additional symptomatic support is needed, rather than addressing external eye issues like infection or surface inflammation. The solution is commonly used to help with lowering intraocular pressure and is used in patients with chronic open-angle glaucoma and intraocular hypertension.

Primary Treatment for Ocular Hypertension and Glaucoma

This medication is primarily relevant in clinical situations characterized by elevated intraocular pressure (IOP), which is a key functional stressor. It is applied across patient groups, including adults and older adults, for the sustained, long-term management of these chronic eye conditions.

Key Therapeutic Benefit: Maintaining Functional Stability

The main benefit of Karteolol is that it supports the management of pressure and contributes to stable levels within the eye. This is relevant for managing conditions that involve noticeable physiological strain. It is often used when supportive relief is needed, and assists with maintaining functional stability.

Quick Fact: Relief for Elevated Intraocular Pressure

Regulatory References

  1. DailyMed National Library of Medicine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Karteol — official regulatory information

The official eligibility profile for Carteolol ophthalmic solution is defined by specific population criteria and absolute contraindications primarily related to its systemic beta-blocking properties.

Eligibility Scope

  • Populations for whom use is allowed (as stated in label): Adults and older adults for treating elevated intraocular pressure.
  • Populations for whom use is contraindicated:
    • Bronchial asthma or a history of bronchial asthma.
    • Severe Chronic Obstructive Pulmonary Disease (COPD).
    • Sinus Bradycardia or Second- and Third-Degree Atrioventricular (AV) Block.
    • Overt Cardiac Failure or Cardiogenic Shock.
    • Known Hypersensitivity to the active substance.

Age-Related Eligibility Rules

  • Use is established in adults and the geriatric population.
  • Safety and effectiveness have not been established in the pediatric population (children and adolescents).

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Classified as Category C. Use should only occur if the potential benefit justifies the potential risk to the fetus.
  • Lactation: Caution is advised for nursing mothers as it is not known whether the drug is excreted in human milk.

Eligibility-Context Constraints

Use requires special caution in patients with diabetes mellitus or thyrotoxicosis, as the medication may mask the clinical signs of acute hypoglycemia or hyperthyroidism. Caution is also advised in patients with non-allergic bronchospasm or those with diminished pulmonary function.

What should I know about interactions with other medicines?

The official interaction profile for Carteolol Hydrochloride Ophthalmic Solution is primarily defined by the risk of additive pharmacodynamic effects from co-administered agents. Combining Carteolol with other medicines that share a similar functional class can potentiate systemic outcomes. The use of two topical beta-adrenergic blocking agents is not recommended due to the potential for excessive systemic exposure and effects.

Carteolol must be used with caution when co-administered with oral beta-adrenergic blocking agents or catecholamine-depleting drugs like Reserpine. This combination carries a documented risk of additive systemic beta-blockade, which may result in severe hypotension or marked bradycardia.

Significant interactions are documented with medicines that affect heart function. Combining Carteolol with oral calcium channel blockers (e.g., Verapamil, Diltiazem), antiarrhythmics (e.g., Amiodarone), and Digitalis glycosides can produce synergistic effects on heart rate and electrical conduction. An increase in beta-blocker plasma concentrations has also been reported when co-administered with Quinidine.

A critical pharmacodynamic note applies to patients on insulin or oral hypoglycemic agents. Carteolol may mask certain signs and symptoms of acute hypoglycemia, such as a fast heartbeat, complicating the recognition of low blood sugar. Regarding administration, Carteolol should be given with separation of several minutes from any other ophthalmic solution. No formal interactions with food, drinks, or alcohol are explicitly documented in the prescribing information.

Mechanism of Action

Karteol operates as a dual-mechanism agent, primarily targeting the intracellular mevalonate pathway. Its initial action is non-competitive inhibition of Farnesyl Pyrophosphate Synthase (FPPS), an enzyme responsible for producing isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).

Inhibiting FPPS prevents the formation of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which serve as required lipid anchors. This blockade disrupts the prenylation of key regulatory proteins, specifically small GTPases such as Rac, Rho, and Rab, rendering them inactive and unable to associate with the cell membrane. The intracellular consequence is the modulation of signaling pathways governing cellular proliferation, adhesion, and migration.

Additionally, Karteol acts at the cell membrane, modulating specific G-protein-coupled receptors (GPCRs) associated with vasoconstrictive signaling. By influencing these GPCRs, Karteol decreases the release of endogenous vasoconstrictors. This action contributes to its overall physiological effect, resulting in the modulation of vascular tone and remodeling.

Dosage and Administration Information

How to use Karteol

Karteol (carteolol) ophthalmic solution is a beta-blocker used topically to lower elevated intraocular pressure (IOP) in individuals with chronic open-angle glaucoma or ocular hypertension. It is typically administered as one drop in the affected eye(s) twice daily, or as directed by a healthcare professional.

Administration Instructions

  • Hand Hygiene and Contamination Prevention: Always wash your hands before applying the drops. To prevent contamination, do not allow the dropper tip to touch your eye, eyelid, hands, or any other surface. A contaminated dropper can lead to serious eye infections.
  • Application Technique: Gently tilt your head back. Using your index finger, pull down the lower eyelid to create a small pocket. Hold the dropper directly over the eye and squeeze the prescribed number of drops into the pocket. Close your eye gently; do not blink or rub the eye.
  • Systemic Absorption Reduction: To minimize the amount of medication that enters the bloodstream, gently press your finger to the inner corner of the eye, near the nose (the tear duct), for one to two minutes immediately after application. This technique may help prevent potential systemic side effects.

Important Considerations

  • Contact Lenses: If you wear soft contact lenses, remove them before applying the drops, as the preservative in the solution may be absorbed by the lens. Wait at least 15 minutes after using the drops before reinserting the contact lenses.
  • Other Ophthalmic Medications: If you are using other eye medications (drops or ointments), apply them at least 10 minutes apart from Karteol to ensure each medication is absorbed properly. Eye drops should generally be used before eye ointments.
  • Missed Dose: If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not use extra drops to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Karteol

The research evidence for Carteolol Ophthalmic Solution is primarily focused on studies evaluating patients with conditions characterized by elevated fluid pressure inside the eye. The available evidence comes mainly from Randomized Controlled Trials (RCTs) and from Systematic Reviews that synthesize the findings of multiple studies.

Evidence for Use in Chronic Open-Angle Glaucoma

Clinical research has extensively examined Carteolol’s profile in adults diagnosed with Chronic Open-Angle Glaucoma. Studies explored the changes in Intraocular Pressure (IOP), which is the key measure for this condition. These trials typically monitored patients over short-term intervals, usually up to three months, to assess how IOP measurements evolved in the observed populations.

Findings describe patterns observed in these studies where the pressure measurements were often found to be consistent with expected outcomes for agents studied in this condition. Research describes that assessments were conducted to see if the medicine was followed by stable measurements in functional outcomes reflecting daily functioning over time.

Evidence for Use in Ocular Hypertension

Research also examined whether Carteolol was observed in patients with Ocular Hypertension (OH), which is characterized by elevated eye pressure without confirmed damage to the optic nerve. The research examined temporary physiological imbalance by monitoring the measured change of elevated IOP. As is standard for this class of medicine, studies also monitored outcomes related to systemic or functional imbalance, such as changes in heart rate and blood pressure, to document the systemic exposure observed during the study period.

What the Research Does Not Fully Address (Uncertainty and Gaps)

The evidence base for Carteolol Ophthalmic Solution is built upon numerous studies for its immediate intended purpose: influencing short-term IOP measurements. One limitation is that follow-up durations were limited in many of the initial comparative trials. While IOP measurements were extensively reported, clinical research requires multi-year studies to definitively capture the long-term impact on functional vision. Data for certain groups, such as pediatric populations, remain insufficient. Research provides context but not individual predictions about the rate of long-term functional decline.

Key Studies & References Label: CARTEOLOL HYDROCHLORIDE solution (US FDA/DailyMed Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Karteol (FAQ)

Q: Is Karteol a type of blood pressure medicine?

Karteol ophthalmic solution is a beta-blocker prescribed primarily to lower pressure inside the eye. The beta-blocker class of medicines is known to affect heart rate and blood pressure. Because of this, official safety information indicates that systemic effects like hypotension (low blood pressure) may be monitored.

Q: How quickly does Karteol start working after you take it?

Official pharmacological data indicates that the therapeutic duration of effect for the ophthalmic solution is typically reported to be 12 hours. This duration relates to the medicine's usual administration schedule.

Q: Is there a generic version of Karteol available?

The active ingredient in this medicine is Carteolol Hydrochloride, which is the generic name. According to regulatory sources, ophthalmic solutions containing this specific active ingredient are available generically.

Q: Why do some people say Karteol makes them tired?

Official regulatory documents and safety lists cite unusual tiredness or weakness as a reported systemic side effect. As a beta-blocker, the medicine belongs to a class known to potentially have effects on the central nervous system, which can sometimes result in feelings of fatigue.

Q: Does Karteol affect your sleep?

Systemic side effects documented in official information, which are consistent with the beta-blocker class, include difficulty sleeping (insomnia) and nightmares.

Q: Is it normal to feel dizzy when first starting Karteol?

Dizziness or lightheadedness is listed in official documents as a less common systemic side effect. Documentation also notes that these systemic side effects are most likely to be seen at the beginning of treatment or if the dosage is adjusted.

Q: Does Karteol interact with common pain relievers like ibuprofen?

Drug interaction data suggests that the oral form of Carteolol may have a moderate interaction with ibuprofen if it is used frequently or regularly. This combination may potentially reduce the blood pressure-lowering effect of the medicine.

Q: How long does Karteol stay in your system?

Pharmacological data from official sources reports that the systemic half-life for the active ingredient is approximately 6 hours. The half-life is the time it takes for half of the drug to be cleared from the body.

Q: Is Karteol safe to use during pregnancy? (Informational)

The medicine is classified as Pregnancy Category C by regulatory authorities. Official documents indicate that use during pregnancy should only occur if the potential benefit is determined to justify the potential risk to the fetus.

Q: Can I stop taking Karteol suddenly if I feel better?

Official safety warnings indicate that sudden discontinuation is not recommended and can lead to adverse health effects. Use of this medicine should only be stopped if specifically instructed by a healthcare professional.

Q: Are there any foods I should avoid while on Karteol?

According to the official prescribing information, formal interactions between the medicine and food are not explicitly documented.

Q: Does Karteol cause weight gain or loss?

Weight gain is cited in official safety information as a symptom that, if experienced suddenly or alongside symptoms like swelling or shortness of breath, should be discussed with a healthcare professional.

Q: Do you need to have regular blood tests while taking Karteol?

Official information notes that laboratory and/or medical tests are performed periodically while using this medicine. Monitoring typically includes eye exams and heart rate checks to track progress and screen for potential systemic effects.

Q: Is Karteol safe for people with diabetes?

Caution is advised for patients with diabetes who are taking insulin or oral agents. This is because the drug may mask certain signs and symptoms of acute hypoglycemia (low blood sugar), such as a fast heartbeat, making it harder to recognize.

Q: Can you take Karteol with multivitamins?

Drug interaction data indicates that using the oral form of Carteolol with a multivitamin that contains minerals may decrease the effects of the medicine. Official information suggests separating administration times by at least 2 hours.

Q: Are the side effects of Karteol more common when you first start taking it?

Documentation notes that certain systemic side effects, such as dizziness or lightheadedness, are most likely to be seen at the beginning of treatment or following a dose adjustment.

Q: Can taking Karteol affect my ability to drive or operate machinery?

Official warnings state that the medicine may cause blurred vision or dizziness. Warnings advise against driving or operating hazardous activity until a patient knows how the medicine affects them.

Q: Is it necessary to take Karteol at the exact same time every day?

Use instructions found in official guidance advise taking the medication at regular intervals to ensure the most consistent benefit. This helps maintain stable pressure in the eye.

Q: Does alcohol interact with Karteol?

Official interaction data indicates that Carteolol and alcohol may have additive effects in lowering blood pressure. This combination could potentially increase the risk of side effects like headache, dizziness, lightheadedness, or changes in heart rate.

Q: Does Karteol affect your blood sugar levels?

Official information notes that this medicine may cause changes in blood sugar levels. Additionally, it can mask the physical signs of low blood sugar, which is a known precaution for patients with diabetes.

Q: Why is my doctor concerned about my heart rate when starting Karteol?

As a beta-blocker, the medicine is known to slow the heart rate, potentially causing bradycardia (a slow heart rate). Official warnings also indicate the potential for the medicine to aggravate overt cardiac failure, which is why heart function monitoring is advised.

Q: What is the typical age range of people prescribed Karteol?

The use of the ophthalmic solution is officially established in adults and the geriatric population. The condition it is approved to treat (elevated intraocular pressure) typically affects these age groups.

Q: Are there different strengths available for Karteol?

The ophthalmic solution is typically commercially available in a 1% concentration (Carteolol Hydrochloride 1%), as stated in official product information.

How should Karteol be stored and disposed of?

The official requirements for the storage and disposal of Carteol Ophthalmic Solution are documented by regulatory authorities to ensure stability and safety.

Storage

  • Store at controlled room temperature ( 15 C to 25 C) and keep from freezing.
  • The product must be protected from light and kept in a tightly closed container.
  • Keep out of the reach of children (and sight of children).
  • Discard after 28 days (or up to 2 months, depending on specific labeling) once the bottle is opened due to sterility constraints.

Disposal

  • The product is not on the FDA flush list and should not be flushed down the toilet or sink.
  • The preferred method of disposal is using a drug take-back program or mail-back envelope.
  • If no take-back option is available, unused medicine must be mixed with an undesirable substance (like coffee grounds), sealed in a container, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Karteol found in:

A-Z Index: